Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UBP-alloNK-19
- Development stage
- Preclinical
- Lead developer
- UWELL Biopharma
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
UBP-alloNK-19 (also known as UWC19-aNK) is an allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by UWELL Biopharma. The therapy consists of natural killer cells engineered to express a CAR targeting CD19, a protein widely expressed on the surface of B-cell malignancies. By utilizing an allogeneic approach, the therapy aims to provide an off-the-shelf treatment option for patients with B-cell cancers, potentially overcoming the manufacturing delays and high costs associated with autologous CAR-T therapies. As of the latest pipeline information, the program is in the preclinical stage, specifically focused on CAR engineering.
- Other names
- UBP-alloNK-19UBP-alloNK19UBP-alloNK 19UWC19-aNKUWC-19-aNKUWC 19-aNK
02
Targets
Beyond the preview
Go deeper on UBP-alloNK-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UBP-alloNK-19.